Mineralys Therapeutics is a biopharmaceutical company focused on developing treatments for cardiometabolic diseases, including its experimental blood pressure drug lorundrostat.
No entity score yet. This entity needs at least one linked article with an entity impact vote and focus support.
Showing 1-1 of 1 linked article
Page 1 of 1
Mineralys Therapeutics’ experimental blood pressure drug lorundrostat lowered systolic blood pressure in a trial of people whose hypertension was still uncontrolled on standard treatment.
Per-entity impact from this article: None